Mesothelioma Foundation Experts Can Answer Your Questions!

The Mesothelioma Applied Research Foundation's team of experts is available to answer your questions about mesothelioma, its symptoms and treatments as well as options available to you. This help is a free service. We are not a law firm. Read more about the Mesothelioma Applied Research Foundation.

TO GET HELP CALL: (877) End-Meso or (877) 363-6376 or fill out the form to the right to be contacted by us.

Facebook Twitter YouTube Google Plus

The Meso Foundation Science Advisory Board: Sanjay Popat, PhD

Meet Sanjay Popat, PhD

Dr. Sanjay Popat is a Consultant Thoracic Medical Oncologist at the Royal Marsden Hospital. He specializes in the treatment of thoracic malignancies: lung cancer, mesothelioma, and thymoma. Dr. Popat qualified from Guy’s and St Thomas’ Hospitals in 1994, completed general medical training at the Royal Brompton, and the Hammersmith Hospital, and medical oncology training at the Royal Marsden Hospital. He was awarded a PhD in Molecular Genetics in 2002 and thereafter undertook a post-doctoral Clinician Scientist Fellowship, and subsequently a HEFCE Clinical Senior Lectureship. He has published in the fields of molecular genetics, therapeutic biomarkers, and medical oncology. He has been awarded nationally and internationally competitive prizes for his research, in addition to 4 research fellowships.

Dr. Popat's research interests include the development of novel drug strategies for the treatment of thoracic cancers through clinical trials, the identification of DNA variants that influence thoracic cancer development and their impact on clinical behavior, as well as the identification of biomarkers predictive of therapeutic effect.

He is co-director for the NIHR London South Clinical Research Network (CRN) Cancer Division and Chair of Cancer for the West London Genomic Medicine Centre. He Chairs the British Thoracic Oncology Group (BTOG), and the UK NCRI Lung Cancer Clinical Studies Group (CSG) Advanced Disease Sub-group. He is active in the European Organization for Research and Treatment of Cancer (EORTC) Lung Group, the European Thoracic Oncology Platform (ETOP), and the International Thymic Malignancy Interest Group (ITMIG).

Back to Science Advisory Board